TrialEBioMedicine2024

Efficacy, safety and genomic analysis of SCT200, an anti-EGFR monoclonal antibody, in patients with fluorouracil, irinotecan and oxaliplatin refractory RAS and BRAF wild-type metastatic colorectal cancer: a phase Ⅱ study.

Lin Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.